Long Wu News Today

Flyer will join us power lunch starts right now welcome to power lunch earnings feeling a big earning today. The dow up triple digits, fueling it caterpillar and 3m, adding 100 points to the dow just by themselves 3m higher by 8 . H r plunging 20 the office maker beat thing at earnings estimates its coming in well short of expectations whirlpool shares are tanking on news that sears will stop selling the brand. Stanley black decker rallying. The toolmaker also raising its full year outlook. Tyle...

Several elegantly dressed grandmas wrapped in neatly pressed traditional damask cheongsams complemented by exquisite makeup and permed gray hair, gracefully walk into the live broadcast rooms spotlight.

China, U.S. combined account for approximately 40% of cancer deaths worldwide annually

ROCKVILLE, Md. and SUZHOU, China, Nov. 30, 2023 /PRNewswire/ -- Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted and granted priority review to the new drug application for IBI351 in the treatment of patients with advanced, KRAS G12C–mutant NSCLC who have received at least 1 prior systemic therapy.

Join us for the first annual Cure4Cancer conference focused on advancing global health equity and harmonization.

Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.

Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

Zorifertinib improves PFS when compared to gefitinib or erlotinib as first-line treatment for EGFR-mutant NSCLC with CNS metastases.